Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-7Rα drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-7Ra/CD127 (IL7R) ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View IL7R Products |
| Gene Delivery | IL-7Ra Lentivirus Premade Particles. Full-length ORF for stable cell line construction (Flow Cytometry/Internalization). | View IL7R Products |
| Benchmark Ab | Anti-IL7R (Sequence of Lusvertikimab biosimilar). Recombinant positive control for blocking assays. | View IL7R Products |
| Validator | IL-7Ra siRNA Set. For knockdown verification and specificity controls. | View IL7R Products |
| Ligand Control | IL-7 Recombinant Protein. Sequence Verified. For competition binding assays. | View IL7 Products |
| Complex Partner & Off-target Counter-screen | IL2RG (Common Gamma Chain) ECD-Fc for heterodimeric complex; CRLF2 (TSLPR) for selectivity testing. | View IL2RG Products, View CRLF2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Silent Antagonism / No Agonism | IL7R ECD-Fc fusion enables SPR/BLI epitope binning to select non-agonist, non-dimerizing clones. |
| Cross-species cyno/mouse evaluation | Human, Cyno, and Mouse IL7R ortholog ECD proteins available with >95% purity and sequence verification. |
| TSLPR Complex Off-target Liability | Homolog panel (IL2RG, TSLPR) proteins strictly verified by mass spec for counter-screening. |
| Heterodimeric Complex Formation (IL-7Ra + γc) | High-purity IL-7Ra and IL-2RG ECD-Fc proteins for co-binding studies; lentivirus-mediated stable cell lines for cellular assays. |
| Ligand Competition (vs IL-7) | Native-conformation IL-7Ra proteins (HEK293 expressed) retaining theoretical IL-7 binding capacity. |
| False Positives / Specificity | Endotoxin controlled (<1EU/ug) reagents and validated siRNA to isolate target-specific effects. |
Live IL-7Ra/CD127/IL7R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ CD127 Specific Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for IL-7Ra therapeutics is bifurcating: autoimmune developers are pursuing silent antagonist antibodies to blunt pathogenic T-cell survival, while oncology programs target gain-of-function IL7R mutations in T-ALL. Because IL-7Ra is a shared receptor chain in both IL-7 and TSLP signaling, next-generation therapeutics focus on epitope-specific blockade to treat autoimmune diseases without severe lymphopenia. As first-generation antagonists (e.g., OSE-127, REP-1) reach Phase II, the next wave includes mutant-specific inhibitors, ADCs, bispecifics (e.g., IL-7R/PD-1), and combination strategies with B-cell depleting agents or cell therapy enhancement. The dichotomy between antagonist development (for SLE/MS/T1D) and IL-7 superagonist strategies (for lymphopenia/CAR-T persistence) creates parallel demand for distinct assay formats—blockade assays versus receptor complex stabilization assays.
Key Mutations and Functional Domains
IL7R (UniProt P16871) contains a Fibronectin type-III domain critical for ligand binding. Key mutations include:
- dbSNP:rs1494558 (UniProt VAR_021286)
- dbSNP:rs11567735 (UniProt VAR_021287)
- IMD104-associated dbSNP:rs104893894 (UniProt VAR_034870) These variants are relevant for understanding differential drug sensitivity and designing mutant-specific inhibitors for T-ALL.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Tizona Therapeutics / AbbVie, OSE Immunotherapeutics, Repertoire Immune Medicines | Type 1 Diabetes, Ulcerative Colitis, Sjögren's Syndrome, MS, SLE | Silent antagonist selection via IL-7 competition SPR/BLI using high-purity IL7R ECD-Fc. |
| IL-7 Superagonist (Ligand-Fc) | NeoImmuneTech (NT-I7) | Cancer Immunotherapy, Lymphopenia, CAR-T Enhancement | Receptor occupancy / internalization assay using IL7R-overexpressing stable cell lines (lentivirus). |
| Mutant-Specific Inhibitor | Academic / Biotech Consortia | T-cell ALL (T-ALL) | Mutant vs WT selectivity screening using IL7R mutant recombinant proteins. |
| Antibody-Drug Conjugates (ADC) | Preclinical Biotech | T-ALL, B-ALL | Internalization assay with HEK293-expressed native glycosylation antigens and lentivirus cell lines. |
| Bispecific Antibodies | Emerging R&D | Complex Autoimmune, Solid Tumors | Epitope binning & heterodimer validation using cross-reactive antibodies and co-expression systems. |
| CAR-T Therapy | Academic / Early Biotech | Refractory Leukemias | Target recognition and activation assessment using lentivirus-driven IL7R stable cell lines. |